uniQure (NASDAQ:QURE) Stock Price Passes Above 50 Day Moving Average - Here's What Happened

Key Points

• uniQure's stock price surpassed its 50-day moving average of $15.29, reaching a high of $16.61 before closing at $14.84 with a trading volume of nearly 3 million shares.
• Various brokerages have given a range of target prices for uniQure, with Cantor Fitzgerald setting the highest target at $47.00, while the consensus target price is approximately $37.45.
• The company reported an earnings per share (EPS) of ($0.69) for its last quarter, beating analysts' estimates of ($0.89), with a quarterly revenue of $5.26 million.

uniQure N.V. (NASDAQ:QURE - Get Free Report) shares crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $15.29 and traded as high as $16.61. uniQure shares last traded at $14.84, with a volume of 2,992,371 shares.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on QURE. Cantor Fitzgerald set a $47.00 target price on uniQure in a research note on Wednesday, July 30th. Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price for the company in a research note on Thursday, August 14th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Friday, September 5th. Chardan Capital restated a "buy" rating and set a $35.00 target price on shares of uniQure in a research note on Monday, September 8th. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $37.45.

uniQure Price Performance

The stock has a 50-day simple moving average of $15.29 and a 200 day simple moving average of $14.01. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The company has a market cap of $814.27 million, a P/E ratio of -3.79 and a beta of 0.13.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. On average, equities analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other news, Director Robert Gut sold 3,336 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $48,205.20. Following the completion of the transaction, the director directly owned 56,879 shares of the company's stock, valued at approximately $821,901.55. This represents a 5.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David D. Meek sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director directly owned 34,190 shares of the company's stock, valued at approximately $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,474 shares of company stock worth $251,722 in the last 90 days. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC increased its holdings in uniQure by 304.4% during the 2nd quarter. Headlands Technologies LLC now owns 42,444 shares of the biotechnology company's stock valued at $592,000 after purchasing an additional 31,948 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares in the last quarter. Corient Private Wealth LLC increased its holdings in uniQure by 100.0% during the 2nd quarter. Corient Private Wealth LLC now owns 21,260 shares of the biotechnology company's stock valued at $296,000 after purchasing an additional 10,630 shares in the last quarter. Shay Capital LLC increased its holdings in uniQure by 21.4% during the 2nd quarter. Shay Capital LLC now owns 99,383 shares of the biotechnology company's stock valued at $1,385,000 after purchasing an additional 17,534 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its holdings in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock valued at $21,723,000 after purchasing an additional 1,012,585 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.